HoldingsJohnson & Johnson, Pfizer, UnitedHealth Group, and more
Managed byState Street Global Advisors
Everybody needs healthcare services at some point in their lives, whether it’s a routine doctor or dentist visit, a prescription drug to help heal an illness, or something more complex like surgery.
In fact, healthcare is one of America’s largest industries. By 2026, spending on health care will jump to $5.7 trillion, according to U.S. federal government projections.
It’s a huge, highly profitable business for numerous companies. And because everyone needs medical care, it’s always going to be in demand. The healthcare system and its associated companies have a broad reach and includes the biotech, pharmaceutical, insurance, and medical providers and devices industries, among others.
For these reasons, the healthcare field is highly attractive to investors. And you can get in on the action with Doctor, Doctor (ticker: XLV) on Stash.
What’s in the fund?
With an aging population—there are more than 50 million Americans over 65, and by 2060, there will be 98 million, or nearly one-quarter of the population—the healthcare industry (along with associated spending) is expected to grow concurrently.
That means big potential returns for health care companies and investors whose portfolios contain those companies.
The fund’s holdings include 61 companies, both big and small, in the healthcare sector. Among the fund’s largest holdings are conglomerates like Johnson & Johnson, which generates revenue from prescription drugs, medical devices, and consumer products like Neutrogena, Band-Aids, and Tylenol. There’s also Pfizer, a 150-year-old global company that makes medications including Viagra and Lipitor, vaccines, and consumer products such as Advil, ChapStick and Centrum. The fund also contains the stock of one of the country’s biggest insurers, United HealthCare.
More than 43% of the fund’s holdings are in pharmaceutical companies, 23.3% are in healthcare equipment manufacturers, and 17% are in healthcare providers.
Doctor, Doctor, which launched in 1998 and has $15.3 billion of assets, is the oldest and largest of its kind. It’s managed by State Street Global Advisors, according to the fund prospectus.
As the healthcare costs have increased, so have earnings for healthcare companies. And returns for holders of Doctor, Doctor. Recent market volatility has put a damper on the fund’s performance, however, as its year-to-date return is -1.2% as of April 2018, according to Morningstar.
The fund has a history of strong returns. In 2013, for example, it returned 41.4%, though that isn’t typical. In 2017, the fund returned 21.77%, and year-to-date, as of April 2018, the fund is actually down -1.2%.
There are numerous other funds focused on the healthcare industry. One is the Vanguard Health Care ETF (ticker: VHT), which tracks the MSCI U.S. Investable Market Health Care 25/50 Index.
VHT contains many of the same assets as Doctor, Doctor, including stocks from big companies like Johnson & Johnson, UnitedHealth, and Merck. And as a result, its returns have followed a similar trajectory.
Year-to-date, as of April 2018, VHT is down -0.16%, according to Morningstar. But in 2017, it had a return of 23.26%. And, like Doctor, Doctor, 2013 was also VHT’s strongest year since 2008, during which it posted a return of 42.67%.
Risks and considerations
The world of healthcare is enormously complicated. Though investing in the industry looks like a slam-dunk, there are plenty of things to consider before going all-in.
Changing laws and regulations, for one, are likely to have a big impact on the sector going forward. Given all of the controversy surrounding the Affordable Care Act, and the recent (and possible) upcoming attempts to amend or repeal the law, healthcare stocks could become more volatile than many investors are comfortable with.
For example, stocks took a wild ride during the most recent congressional push to repeal the Affordable Care Act, soaring only after a replacement plan was voted down in the Senate.
Aside from industry concerns, there’s also risk centered around the fund’s lack of diversification. It’s 61 total holdings are all U.S.-based, and it only invests in one sector.
The fund has an expense ratio of 0.13%, which is well below average, according to industry data.